Skip to main content
SpringerLink
Log in

Pharmacokinetic studies of cimetidine in patients with liver disease

  • Original Article
  • Published:
Gastroenterologia Japonica Aims and scope Submit manuscript

Summary

The tolerability and metabolism of cimetidine administered for over 7 days were studied in 30 patients with liver diseases and 19 control subjects who had peptic ulcers. Cimetidine was well tolerated by these patients without any side effects. The cimetidine in the serum and urine was determined by highperformance liquid chromatography.

The serum cimetidine levels and pharmacokinetic parameters of the patient group did not significantly differ from those of the control group after oral administration. Following intravenous administration, the half-life of cimetidine increased and cimetidine clearance decreased in the liver disease group. These differences seem to be totally explicable by the impaired renal function associated with the liver disease. Furthermore, accumulation of cimetidine in serum did not occur following continuous treatment with cimetidine in these patients.

It was concluded that a reduction of cimetidine dosage is not necessary in patients with liver disease as far as their renal function is not disturbed, since the metabolism of cimetidine was not affected by the liver dysfunction itself.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Walkenstein SS, et al: Bioavailability of cimetidine in man. Gastroenterology 1978, 74: 360

    PubMed  CAS  Google Scholar 

  2. Bodemar G, et al: Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinetics 1981, 6: 306

    Article  CAS  Google Scholar 

  3. Larsson R, et al: Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol 1979, 15: 153

    Article  PubMed  CAS  Google Scholar 

  4. Guay DRP, et al: Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. Clinical Pharmacy 1983, 2: 157

    PubMed  CAS  Google Scholar 

  5. Sonne J, et al: Cimetidine clearance and bioavailability in hepatic cirrhosis. Clin Pharmacol Ther 1981, 29: 191

    Article  PubMed  CAS  Google Scholar 

  6. Okolicsanyi L, et al: Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 1982, 20: 482

    PubMed  CAS  Google Scholar 

  7. Porro GB, et al: Blood levels of cimetidine in patients with liver cirrhosis. Int J Clin Pharmacol Ther Toxicol 1983, 21: 374

    Google Scholar 

  8. Gugler R, et al: Altered disposition and availavility of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol 1982, 14: 421

    PubMed  CAS  Google Scholar 

  9. Villeneuve JP, et al: Cimetidine kinetics and dynamics in patients with severe liver disease. Hepatology 1983, 3:923

    Article  PubMed  CAS  Google Scholar 

  10. Gonzalez-Martin G, et al: Pharmacokinetics of cimetidine in patients with liver disease. Int J Clin Pharmacol Ther Toxicol 1985, 23: 355

    PubMed  CAS  Google Scholar 

  11. Guay DRP, et al: High-performance liquid chromatographic analysis of cimetidine in serum and urine. J Chromatogr 1982, 228: 398

    Article  PubMed  CAS  Google Scholar 

  12. MacDougall BRD, et al: H2-receptor antagonists and antacids in the prevention of acute gastrointestinal hemorrhage in fulminant hepatic failure. Lancet 1977, 1: 617

    Article  PubMed  CAS  Google Scholar 

  13. Schentag JJ, et al: Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1979, 1: 177

    Article  PubMed  CAS  Google Scholar 

  14. Kimelblatt BJ, et al: Dose and serum concentration relationships in cimetidine-associated mental confusion. Gastroenterology 1980, 78: 791

    PubMed  CAS  Google Scholar 

  15. Schentag JJ, et al: Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 1981, 29: 737

    Article  PubMed  CAS  Google Scholar 

  16. Burland WL, et al: Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol 1975, 2: 481

    PubMed  CAS  Google Scholar 

  17. Taylor DC, et al: The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog, and man. Drug Metab Dispos 1978, 6: 21

    PubMed  CAS  Google Scholar 

  18. Ma KW, et al: Effects of renal failure on blood levels of cimetidine. Gastroenterology 1978, 74: 473

    PubMed  CAS  Google Scholar 

  19. Norlander B, et al: Therapeutic plasma concentrations of cimetidine in normal renal function and dosage requirements in renal failure. Ther Drug Monit 1980, 2: 147

    Article  PubMed  CAS  Google Scholar 

  20. Drayer DE, et al: Age and renal clearance of cimetidine. Clin Pharmacol Ther 1982, 31: 45

    Article  PubMed  CAS  Google Scholar 

  21. Kew MC, et al: Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971, 2: 504

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Okayama University Medical School, 2-5-1 Shikata-cho, 700, Okayama, Japan

    Hiroko Yamasaki M.D, Terukatsu Arima M.D & Hideo Nagashima M.D

Authors
  1. Hiroko Yamasaki M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terukatsu Arima M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideo Nagashima M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamasaki, H., Arima, T. & Nagashima, H. Pharmacokinetic studies of cimetidine in patients with liver disease. Gastroenterol Jpn 22, 440–447 (1987). https://doi.org/10.1007/BF02773811

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02773811

Key Words

Search

Navigation